Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.
about
Failure or success of search strategies to identify adverse effects of medical devices: a feasibility study using a systematic reviewDrug safety surveillance using de-identified EMR and claims data: issues and challengesEvaluating harm associated with anti-malarial drugs: a survey of methods used by clinical researchers to elicit, assess and record participant-reported adverse events and related data.Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesRapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint BlockadeFailure or success of electronic search strategies to identify adverse effects data.A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year.The efficacy and safety of the herbal medicine geonchildan for patients with active rheumatoid arthritis: study protocol for a randomized, double-blind, placebo-controlled, parallel pilot trialCombination treatment of captopril and prazosin to treat patients with gestational hypertensionImmune-related adverse events of immune checkpoint inhibitors: a brief reviewPhase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate
P2860
Q28249675-0B129556-A9FF-4D16-85FF-1F66F74AF298Q28385191-9A4F47CA-5574-4FA7-AD97-3A8AE99301D0Q30667272-67E2A9FB-96C5-4FBE-941B-04557B6BD253Q33578361-2FC1F16D-D884-43AC-B580-59CF0CCD0D39Q33737181-5A59684D-101D-431D-80AE-171E6A8B7359Q33793552-7133BB02-045C-419E-9376-E3B66D251D36Q34238325-37B87A65-F375-4AD1-9D90-C0BF87E6710FQ34533371-9DAD71B4-D146-43CE-9589-3E38298AC093Q34533379-6019A743-2C06-4865-B561-409FE71FFDF9Q34818636-4F727498-4282-4C0C-8336-98E384F29ECDQ35605477-28EC30CB-AC44-43E6-9EC8-A9B51D77F7EFQ38097129-2EB53D0F-A48B-454C-A80A-B8B5723A9616Q38734760-3992FD9E-2F54-4929-A488-44F88C151C80Q39021248-61461D0A-479F-4D22-B1EC-70FC0AFB52DEQ39044741-A52D9984-323E-47E3-BFAA-4291113A4D2EQ47102520-33E119F1-8A88-438C-93AA-221808EBEB7FQ50626424-903DD865-4512-4EB5-BB5F-FE3FB0759F0EQ53837944-E8E07D91-9C4B-4BF6-BB75-B1D36E245850Q55286574-B5D09933-97A1-4FD5-BDC7-99B26C5C9468Q55331950-7C68DDD8-AA41-4277-9492-61CA62097239Q57213110-545BA331-E01B-4CA8-9F28-3E59E86B6D5DQ58784202-EBC14854-7813-4C91-85F9-98A2FFAC9765Q59126189-797A19DB-BCF9-45DA-B24E-BA9D42A62B4DQ59137786-436C1925-6697-4ECB-B307-A11AEDF049CC
P2860
Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Standardizing assessment and r ...... ommon Toxicity Criteria v.2.0.
@en
type
label
Standardizing assessment and r ...... ommon Toxicity Criteria v.2.0.
@en
prefLabel
Standardizing assessment and r ...... ommon Toxicity Criteria v.2.0.
@en
P2093
P1476
Standardizing assessment and r ...... ommon Toxicity Criteria v.2.0.
@en
P2093
Clifton O Bingham
Daniel E Furst
David Yocum
James Fries
James Witter
Kent Johnson
Marissa Lassere
Peter Brooks
Randall Stevens
Rieke Alten
P304
P407
P577
2007-06-01T00:00:00Z